CLTX: Celsus Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTX: Celsus Therapeutics

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (34)	3/13/2002 8:21:22 AM
From: mopgcw	Read Replies (1) of 40

Collateral Thera Buys Rights to the EPAS1 Gene DOW JONES NEWSWIRES SAN DIEGO -- Collateral Therapeutics Inc. (CLTX) signed an option agreement to license exclusive worldwide gene therapy rights for the Endothelial PAS domain protein 1, or EPAS1, gene from the University of Texas Southwestern Medical Center at Dallas Financial terms of the agreement weren't disclosed. Collateral said in a press release Wednesday it plans to evaluate the development and potential commercialization of EPAS1 in its ongoing non-surgical cardiovascular gene therapy programs. The company said EPAS1 is a naturally occurring hypoxia-inducible transcription factor that is predominantly expressed in endothelial cells such as those lining the walls of blood vessels. Early preclinical studies show that the EPAS1 gene can activate expression of other genes involved in blood vessel development, and may enhance cardiac output, Collateral added. The gene has a U.S. patent. The company said the new gene broadens its therapeutic genes portfolio and expands commercial opportunities in the cardiovascular angiogenic gene therapy field. Collateral Therapeutics discovers and develops gene therapy products for the treatment of cardiovascular diseases.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next